Paradigm to launch Glaid-PERG for Glaucoma detection
Paradigm Medical Industries plans to introduce the Glaid-PERG electrophysiology instrument for the early detection of Glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, Illinois, in April. The company’s CEO Raymond Cannefax said, “All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments.” The early diagnosis of Glaucoma, which causes the most cases of vision loss, will help reduce these cases.

Researchers at the University of Utah School of Medicine and other institutes have announced that age-related macular degeneration and diabetic retinopathy could be prevented or reversed by activating a protein, Robo4, in blood vessel cells through drugs. The research was conducted in mice models simulating age-related macular degeneration (AMD) and diabetic retinopathy. The protein acted by inhibiting abnormal blood vessel growth and preventing leakage by stabilizing blood vessels.